CinRx Pharma

CinRx Pharma was launched in September of 2015 to transform the development of innovative therapies addressing substantial unmet medical needs. With leading CRO Medpace as a strategic partner, CinRx leverages its cost-efficient structure while having access to global clinical development expertise and networks of advisors, critical understanding of the evolving regulatory environment, and industry-leading track records of execution across all stages of R&D. CinRx’s therapeutic pipeline focuses on innovative and disruptive new molecular entities (NMEs). CinRx pursues an expedited path of development to achieve significant value inflection points for each of its programs. Once a compound has demonstrated clinical and commercial value, CinRx will determine the optimal strategy to bring the product to patients.

Data last updated: June 2026